Maxim Group Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $5
Portfolio Pulse from richadhand@benzinga.com
Maxim Group analyst Naz Rahman has initiated coverage on Aytu BioPharma with a Buy rating and a price target of $5.
August 09, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aytu BioPharma has been given a Buy rating by Maxim Group with a price target of $5.
The Buy rating and price target set by Maxim Group is a positive signal for Aytu BioPharma. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100